This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chang, J. Articles by Ragu, G. C. Search for Related Content PubMed PubMed Citation Articles by Chang, J. Articles by Ragu, G. C.

Pathological Features and BRCA1 Mutation Screening in Premenopausal Breast Cancer Patients¹

Breast Center, Baylor College of Medicine, Houston Texas 77030, and Departments of Medical Oncology and Pathology, National University of Singapore, Singapore 0511

Purpose: Risk calculations for carrying BRCA1/BRCA2 mutations are based on family history and the age of onset of cancers. However, women may carry these deleterious mutations without a strong family history. Additional criteria for risk estimation would be of value. It has been recently established that BRCA1-associated breast cancers are associated with poor tumor differentiation (TD3) and estrogen receptor (ER) negativity. The aim of this study is to determine whether morphological features of breast cancers in premenopausal patients (age < 45 years) could determine additional women who may benefit from BRCA1 screening.

Experimental Design: In a prospective, systematic study of 76 consecutive breast cancer patients (age < 45 years), genomic DNA was obtained from peripheral blood, and eight mutations in BRCA1 (10.5%) were found. Archival paraffin-embedded breast cancer specimens were then analyzed for tumor differentiation and ER status.

Results: In patients < 45 years of age, 25% (6 of 24) of ER-negative and TD3 breast cancers were found to harbor mutations in BRCA1. Only 5.6% (2 of 36) of BRCA1-associated breast cancers did not have this morphological profile, compared with 94.4% (34 of 36) patients without BRCA1 mutations, giving an odds ratio of 5.67 (95% confidence interval, 1.04–32; P = 0.05). Finally, only one patient with BRCA1 mutations had a significant family history.

Conclusions: In patients with early-onset breast cancer, the use of morphological criteria provides an additional strategy to determine those patients who might benefit from genetic testing.

This article has been cited by other articles:

				B. G. Haffty, D. H. Choi, S. Goyal, A. Silber, K. Ranieri, E. Matloff, M. H. Lee, M. Nissenblatt, D. Toppmeyer, and M. S. Moran Breast cancer in young women (YBC): prevalence of BRCA1/2 mutations and risk of secondary malignancies across diverse racial groups Ann. Onc., June 2, 2009; (2009) mdp051v1. [Abstract] [Full Text] [PDF]

				D. H. Choi, M. H. Lee, A. E. Bale, D. Carter, and B. G. Haffty Incidence of BRCA1 and BRCA2 Mutations in Young Korean Breast Cancer Patients J. Clin. Oncol., May 1, 2004; 22(9): 1638 - 1645. [Abstract] [Full Text] [PDF]

				M. G. Daidone, S. Veneroni, V. Cappelletti, P. Radice, M. A. Pierotti, M. Younes, L. Scheuer, N. D. Kauff, M. E. Robson, and K. Offit Estrogen Receptor-Beta Expression in Hereditary Breast Cancer J. Clin. Oncol., September 1, 2002; 20(17): 3752 - 3753. [Full Text] [PDF]

				S. R. Lakhani, M. J. van de Vijver, J. Jacquemier, T. J. Anderson, P. P. Osin, L. McGuffog, and D. F. Easton The Pathology of Familial Breast Cancer: Predictive Value of Immunohistochemical Markers Estrogen Receptor, Progesterone Receptor, HER-2, and p53 in Patients With Mutations in BRCA1 and BRCA2 J. Clin. Oncol., May 1, 2002; 20(9): 2310 - 2318. [Abstract] [Full Text] [PDF]